This paper from Belgrade, Serbia, reports on the experience of the authors in 47 patients with short scar brachioplasty in combination with posterolateral liposuction for the treatment of brachial lipodystrophy in selected cases. With this large series, a better understanding of the technique......

This paper from Belgrade, Serbia, reports on the experience of the authors in 47 patients with short scar brachioplasty in combination with posterolateral liposuction for the treatment of brachial lipodystrophy in selected cases. With this large series, a better understanding of the technique and expected results may be easily afforded by the specialized surgeon. Back >

The subfraction of highly atherogenic LDL circulates in the blood of diabetic patients; it is represented by in vivo multiply-modified small, more dense, more electronegative and desialylated LDL particles. This LDL subfraction may be assigned to play a significant role in early and......

The subfraction of highly atherogenic LDL circulates in the blood of diabetic patients; it is represented by in vivo multiply-modified small, more dense, more electronegative and desialylated LDL particles. This LDL subfraction may be assigned to play a significant role in early and accelerated atherogenesis in diabetes mellitus. Back >

Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies that could develop at any level from the biliary tree. CCA is currently classified into intrahepatic (iCCA), perihilar and distal on the basis of its anatomical location. Of note, these three CCA subtypes have common features......

Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies that could develop at any level from the biliary tree. CCA is currently classified into intrahepatic (iCCA), perihilar and distal on the basis of its anatomical location. Of note, these three CCA subtypes have common features but also important inter-tumor and intra-tumor differences that can affect the pathogenesis and outcome. Back >

MicroRNA-126 was involved in angiogenesis during physiological and pathological process. It was mainly expressed in endothelial cells, and defined as a pivotal biological molecule associated with vascular disease. Increased microRNA-126 in endothelial cells promotes angiogenesis in ischemic......

MicroRNA-126 was involved in angiogenesis during physiological and pathological process. It was mainly expressed in endothelial cells, and defined as a pivotal biological molecule associated with vascular disease. Increased microRNA-126 in endothelial cells promotes angiogenesis in ischemic stroke, repairs impaired endothelial cells in atherosclerosis, and attenuates vascular dysfunction in diabetics. By contrast, microRNA-126 transferred from endothelial cell to smooth muscle cells could lead to proliferation that induced intimal hyperplasia. Additionally, microRNA-126 could be a tumor suppressor or an oncogene, which was depended on the cancer type. In this review, we summarized the function of microRNA-126 in ischemic stroke, atherosclerosis, diabetics, tumor, and discussed the underlying mechanisms. Back >

Cancer immunotherapy is heralded as one of the most important advances in oncology. Neoantigen vaccines in particular are beneficiaries to cancer patients and are poised to lead the way to more effective therapies. This review paper provides insights into how the thinking process has been......

Cancer immunotherapy is heralded as one of the most important advances in oncology. Neoantigen vaccines in particular are beneficiaries to cancer patients and are poised to lead the way to more effective therapies. This review paper provides insights into how the thinking process has been formulated to achieve the impressive clinical results. Back >

Over years, the focus of cancer treatment has shifted from treating the disease site to treating the specific tumor biologic characteristics and its interaction with intrinsic immunological ability of the patient to combat the disease. This article details the historical development with......

Over years, the focus of cancer treatment has shifted from treating the disease site to treating the specific tumor biologic characteristics and its interaction with intrinsic immunological ability of the patient to combat the disease. This article details the historical development with particular emphasis on immune checkpoint inhibitors. Back >